Pacific Pharm.: license-in of anti-osteoporosis drug.

Pacific Pharmaceutical made a license agreement with Gador SA, an Argentina pharmaceutical company, on Oct. 31 for a joint research and licensing of olpadronate, a family of the bisphonphonate, anti-osteoporosis drugs.

Olpadronate was already proved of its efficacy and safety and on the way of clinical studies for the treatment of Paget disease in Argentina.

The agreement describes that ...